Aurinia – $28.75 Million Offering

Palo Alto – January 6, 2017 – Cooley advised Aurinia Pharmaceuticals on its $28.75 million public offering of 12,777,775 units of the company. Each unit consists of one common share of the company and one-half of one common share purchase warrant. The underwriters exercised their option to purchase $3.75 million worth of additional units.

Aurinia, which is headquartered in Victoria, British Columbia and trades on the NASDAQ Global Market under the symbol “AUPH,” is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
John McKenna Partner, Palo Alto
Carol Laherty Partner, Seattle
Natasha Leskovsek Partner, Washington, DC
Aaron Pomeroy Partner, Colorado
Francis Wheeler Partner, Colorado
Stephanie Gentile Partner, New York